Ryan joined NEA in 1996, and became a General Partner in 2004. He specializes in healthcare investments in the medical device, healthcare information technology and specialty pharma sectors. Present board memberships include BENU, Carticept Medical, Cartiva Medical, DSI Renal, Earlens, ExploraMed III, Intrinsic Therapeutics, Neotract, PatientKeeper, Radiology Partners, Solace Therapeutics, Spine Wave and TriVascular (Nasdaq:TRIV). Ryan also serves on the board of the Medical Device Manufacturers Association.
Past board memberships include Concentric Medical (acquired by Stryker), CVIngenuity (acquired by Covidien), ESP Pharma (acquired by Protein Design Labs, Inc.), Esprit Pharma (acquired by Allergan), FoxHollow Technologies (acquired by EV3, now Covidien), Provation Medical (acquired by Wolters Kluwer), Proxima Therapeutics (acquired by Cytyc Corporation, now Hologic), and Ulthera (acquired by Merz Pharma). Ryan also co-led NEA’s investment in Xcel Pharmaceuticals (acquired by Valeant Pharmaceuticals, Inc.). Prior to joining NEA, Ryan was with the Health Care Investment Banking Group of Alex. Brown & Sons in San Francisco. Previously, he worked in the San Francisco office of Arthur Andersen & Co. Ryan received a BA from Stanford University.